Clincosm LogoSign in Get a demo

Adaptive Radiation for Abdominopelvic Metastases

Sponsor
Fox Chase Cancer Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05880667
Collaborator
(none)
30
Enrollment
71
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.

Condition or Disease Intervention/Treatment Phase
  • Radiation: Adaptive Stereotactic Body Radiation
 Phase 1

Detailed Description

This is a dose-escalation study where the objective is to find the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of adaptive SBRT for abdominopelvic SBRT. There are 3 doses of interest 8Gy/fraction (level 1), 9Gy/fraction (level 2), and 10Gy/fraction (level 3). The starting dose will be level 2. We will use a Bayesian Optimal Interval Design (BOIN) to define dose escalation and de-escalation rules based on the proportion of patients experiencing a dose-limiting toxicity (DLT). DLT events are Grade 3 events possibly, probably, or definitely related to the study intervention.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Adaptive Radiation for Abdominopelvic Metastases (ARAM)
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2028
Anticipated Study Completion Date :
Jun 1, 2029

Outcome Measures

Primary Outcome Measures

  1. To assess the ability of adaptive SBRT to deliver increased doses of radiation safely to patients with challenging anatomical locations of metastatic disease without causing unacceptable toxicity. [3 months]

    Cohorts of size 10 will be enrolled, Severe (grade 3) toxicity occurring within 3 months of treatment that is possibly, probably, or definitely related to trial therapy will be assessed.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Subjects must have histologically or cytologically confirmed cancer that is metastatic (all solid tumor types accepted), with at least one target lesion untreated by radiation, IR techniques, or growing in the abdomen or pelvis. Adjacent lymph nodes in the same region (5 cm or closer) constitute one active lesion. Target lesion must be measurable according to RECIST v 1.1. Previous systemic therapies are allowed.

  2. Age > 18 years.

  3. ECOG performance status 0 or 1

  4. Estimated survival of >/= 12 months

  5. Subjects must have normal organ and marrow function as defined below

  • Absolute neutrophil count > 1,500/mcL

  • Platelets > 100,000/mcL

  • Total bilirubin < 2 mg/dL

  • AST/ALT (SGOT/SGPT) < 5X ULN

  • Creatinine < 1.5X ULN OR

  • Creatinine clearance ≥ 50 ml/min/1.73 m2 for subjects with creatinine levels above institutional normal

  1. Subjects must possess the ability to understand and willingness to sign a written informed consent and HIPAA consent document. Translation services including translation of informed consent documents will be provided, as feasible, to encourage diversity of inclusion of eligible patients.
Exclusion Criteria:

  1. Subjects must not be experiencing toxicity due to prior therapy that has not resolved to ≤Grade 1 by study registration, with the exception of sensory neuropathy related to previous systemic therapy exposure, alopecia and fatigue.

  2. Subjects must not be receiving any other investigational agents.

  3. Subjects must not have known peritoneal carcinomatosis visible on imaging.

  4. Subjects must not have known active solid tumors on imaging outside of abdomen/pelvis noted on screening imaging

  5. Subjects must not have 6 or more active metastatic sites.

  6. Subjects must not have had prior radiotherapy to any target metastatic lesion. Prior radiotherapy to non-target sites is allowed.

  7. Subjects must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

  8. Any condition or significant co-morbidity that prevents safe delivery of SBRT per the discretion of the treating physician(s).

  9. Subjects must not be pregnant or breast-feeding. Refer to section 4.4 for further detail.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Fox Chase Cancer Center

Investigators

  • Principal Investigator: Joshua Meyer, MD, Fox Chase Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Fox Chase Cancer Center
ClinicalTrials.gov Identifier:
NCT05880667
Other Study ID Numbers:
  • RT-218
First Posted:
May 30, 2023
Last Update Posted:
May 30, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Neoplasms
Stomach Neoplasms

Study Results

No Results Posted as of May 30, 2023